Lynch Regenerative Medicine Enhances Portfolio with GEM 21S Distribution Rights Lynch Regenerative Medicine expands its regenerative portfolio by acquiring distribution rights for GEM 21S, a transformative growth factor product designed for therapeutic and cosmetic uses.

Lynch Regenerative Medicine Enhances Portfolio with GEM 21S Distribution Rights #United_States #Franklin #Lynch_Regenerative_Medicine #GEM_21S #PDGF